News | February 18, 2023
Lupin receives EIR from USFDA for injectable facility in Nagpur
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
Themis will market this drug with the brand name REMITHEM.
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
The company has reported total income of Rs.129.14 crores during the period ended December 31, 2022 as compared to Rs.157.54 crores during the period ended December 31, 2021.
Qure.ai is scaling-up the integration of its AI-powered chest x-ray interpretation tool that can benefit early and easy detection of lung diseases including lung cancer.
Strategic partnership aims to support significant growth of the Ibuprofen product market in Brazil and is backed by Univar Solutions' state-of-the-art Solution Center in São Paulo, Brazil
Subscribe To Our Newsletter & Stay Updated
